Cargando…
The Effect of a Cellular-Enabled Glucose Meter on Glucose Control for Patients With Diabetes: Prospective Pre-Post Study
BACKGROUND: Diabetes is a global epidemic affecting approximately 30 million people in the United States. The World Health Organization recommends using technology and telecommunications to improve health care delivery and disease management. The Livongo for Diabetes Program offers a remote monitori...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803884/ https://www.ncbi.nlm.nih.gov/pubmed/31593545 http://dx.doi.org/10.2196/14799 |
_version_ | 1783461049380372480 |
---|---|
author | Bollyky, Jennifer B Melton, Stephanie T Xu, Tong Painter, Stefanie L Knox, Brian |
author_facet | Bollyky, Jennifer B Melton, Stephanie T Xu, Tong Painter, Stefanie L Knox, Brian |
author_sort | Bollyky, Jennifer B |
collection | PubMed |
description | BACKGROUND: Diabetes is a global epidemic affecting approximately 30 million people in the United States. The World Health Organization recommends using technology and telecommunications to improve health care delivery and disease management. The Livongo for Diabetes Program offers a remote monitoring technology with Certified Diabetes Educator outreach. OBJECTIVE: The purpose of this study was to examine health outcomes measured by changes in HbA(1c), in time in target blood glucose range, and in depression symptoms for patients enrolled in a remote digital diabetes management program in a Diabetes Center of Excellence setting. METHODS: The impact of the Livongo for Diabetes program on hemoglobin A(1c) (HbA(1c)), blood glucose ranges, and depression screening survey results (Patient Health Questionnaire-2 [PHQ-2]) were assessed over 12 months in a prospective cohort recruited from the University of South Florida Health Diabetes Home for Healthy Living. Any patient ≥18 years old with a diagnosis of diabetes was approached for voluntary inclusion into the program. The analysis was a pre-post design for those members enrolled in the study. Data was collected at outpatient clinic visits and remotely through the Livongo glucose meter. RESULTS: A total of 86 adults were enrolled into the Livongo for Diabetes program, with 49% (42/86) female, an average age of 50 (SD 15) years, 56% (48/86) with type 2 diabetes mellitus, and 69% (59/86) with insulin use. The mean HbA(1c) drop amongst the group was 0.66% (P=.17), with all participants showing a decline in HbA(1c) at 12 months. A 17% decrease of blood glucose checks <70 mg/dL occurred concurrently. Participants with type 2 diabetes not using insulin had blood glucose values within target range (70-180 mg/dL) 89% of the time. Participants with type 2 diabetes using insulin were in target range 68% of the time, and type 1 diabetes 58% of the time. Average PHQ-2 scores decreased by 0.56 points during the study period. CONCLUSIONS: Participants provided with a cellular-enabled blood glucose meter with real-time feedback and access to coaching from a certified diabetes educator in an outpatient clinical setting experienced improved mean glucose values and fewer episodes of hypoglycemia relative to the start of the program. |
format | Online Article Text |
id | pubmed-6803884 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | JMIR Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-68038842019-11-18 The Effect of a Cellular-Enabled Glucose Meter on Glucose Control for Patients With Diabetes: Prospective Pre-Post Study Bollyky, Jennifer B Melton, Stephanie T Xu, Tong Painter, Stefanie L Knox, Brian JMIR Diabetes Original Paper BACKGROUND: Diabetes is a global epidemic affecting approximately 30 million people in the United States. The World Health Organization recommends using technology and telecommunications to improve health care delivery and disease management. The Livongo for Diabetes Program offers a remote monitoring technology with Certified Diabetes Educator outreach. OBJECTIVE: The purpose of this study was to examine health outcomes measured by changes in HbA(1c), in time in target blood glucose range, and in depression symptoms for patients enrolled in a remote digital diabetes management program in a Diabetes Center of Excellence setting. METHODS: The impact of the Livongo for Diabetes program on hemoglobin A(1c) (HbA(1c)), blood glucose ranges, and depression screening survey results (Patient Health Questionnaire-2 [PHQ-2]) were assessed over 12 months in a prospective cohort recruited from the University of South Florida Health Diabetes Home for Healthy Living. Any patient ≥18 years old with a diagnosis of diabetes was approached for voluntary inclusion into the program. The analysis was a pre-post design for those members enrolled in the study. Data was collected at outpatient clinic visits and remotely through the Livongo glucose meter. RESULTS: A total of 86 adults were enrolled into the Livongo for Diabetes program, with 49% (42/86) female, an average age of 50 (SD 15) years, 56% (48/86) with type 2 diabetes mellitus, and 69% (59/86) with insulin use. The mean HbA(1c) drop amongst the group was 0.66% (P=.17), with all participants showing a decline in HbA(1c) at 12 months. A 17% decrease of blood glucose checks <70 mg/dL occurred concurrently. Participants with type 2 diabetes not using insulin had blood glucose values within target range (70-180 mg/dL) 89% of the time. Participants with type 2 diabetes using insulin were in target range 68% of the time, and type 1 diabetes 58% of the time. Average PHQ-2 scores decreased by 0.56 points during the study period. CONCLUSIONS: Participants provided with a cellular-enabled blood glucose meter with real-time feedback and access to coaching from a certified diabetes educator in an outpatient clinical setting experienced improved mean glucose values and fewer episodes of hypoglycemia relative to the start of the program. JMIR Publications 2019-10-07 /pmc/articles/PMC6803884/ /pubmed/31593545 http://dx.doi.org/10.2196/14799 Text en ©Jennifer B Bollyky, Stephanie T Melton, Tong Xu, Stefanie L Painter, Brian Knox. Originally published in JMIR Diabetes (http://diabetes.jmir.org), 07.10.2019 https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Diabetes, is properly cited. The complete bibliographic information, a link to the original publication on http://diabetes.jmir.org/, as well as this copyright and license information must be included. |
spellingShingle | Original Paper Bollyky, Jennifer B Melton, Stephanie T Xu, Tong Painter, Stefanie L Knox, Brian The Effect of a Cellular-Enabled Glucose Meter on Glucose Control for Patients With Diabetes: Prospective Pre-Post Study |
title | The Effect of a Cellular-Enabled Glucose Meter on Glucose Control for Patients With Diabetes: Prospective Pre-Post Study |
title_full | The Effect of a Cellular-Enabled Glucose Meter on Glucose Control for Patients With Diabetes: Prospective Pre-Post Study |
title_fullStr | The Effect of a Cellular-Enabled Glucose Meter on Glucose Control for Patients With Diabetes: Prospective Pre-Post Study |
title_full_unstemmed | The Effect of a Cellular-Enabled Glucose Meter on Glucose Control for Patients With Diabetes: Prospective Pre-Post Study |
title_short | The Effect of a Cellular-Enabled Glucose Meter on Glucose Control for Patients With Diabetes: Prospective Pre-Post Study |
title_sort | effect of a cellular-enabled glucose meter on glucose control for patients with diabetes: prospective pre-post study |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803884/ https://www.ncbi.nlm.nih.gov/pubmed/31593545 http://dx.doi.org/10.2196/14799 |
work_keys_str_mv | AT bollykyjenniferb theeffectofacellularenabledglucosemeteronglucosecontrolforpatientswithdiabetesprospectiveprepoststudy AT meltonstephaniet theeffectofacellularenabledglucosemeteronglucosecontrolforpatientswithdiabetesprospectiveprepoststudy AT xutong theeffectofacellularenabledglucosemeteronglucosecontrolforpatientswithdiabetesprospectiveprepoststudy AT painterstefaniel theeffectofacellularenabledglucosemeteronglucosecontrolforpatientswithdiabetesprospectiveprepoststudy AT knoxbrian theeffectofacellularenabledglucosemeteronglucosecontrolforpatientswithdiabetesprospectiveprepoststudy AT bollykyjenniferb effectofacellularenabledglucosemeteronglucosecontrolforpatientswithdiabetesprospectiveprepoststudy AT meltonstephaniet effectofacellularenabledglucosemeteronglucosecontrolforpatientswithdiabetesprospectiveprepoststudy AT xutong effectofacellularenabledglucosemeteronglucosecontrolforpatientswithdiabetesprospectiveprepoststudy AT painterstefaniel effectofacellularenabledglucosemeteronglucosecontrolforpatientswithdiabetesprospectiveprepoststudy AT knoxbrian effectofacellularenabledglucosemeteronglucosecontrolforpatientswithdiabetesprospectiveprepoststudy |